Authorities in 27 European countries have approved ALK's tablet-based vaccine
against grass pollen allergy, GRAZAX®, for treatment of children and
adolescents (5 - 17 years old) suffering from grass pollen induced hay fever.
The approval of GRAZAX® for children is a major milestone in the development of
tablet-based allergy vaccines as it makes causal allergy treatment available to
an important patient segment.
Today, most children suffering from grass pollen allergy are only treated with
symptom-relieving medications, such as oral antihistamines or nasal steroids,
which treat the symptoms but not the cause of the disease. GRAZAX® is the first
allergy tablet to treat the underlying cause of grass pollen allergy with
documented persistent effect after completion of treatment. GRAZAX® is now also
the first allergy tablet of its kind to be approved for treatment of children.
In September 2006, GRAZAX® was approved in Europe for adult patients.
This announcement does not change ALK's financial outlook for 2008.
ALK-Abelló A/S
Jens Bager
President and CEO
For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576
Investor Relations: Per Plotnikof, tel +45 4574 7527, mobile +45 2261 2525
Press: Jacob Frische, tel +45 4574 7551, mobile +45 2224 7551
For further information, please see attached pdf-file.
